The "The Veterinary Drug Approval Process and FDA Regulatory Oversight" conference has been added to ResearchAndMarkets.com's offering.

The U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) is responsible for the approval of veterinary drug products intended for family pets, food-producing animals, and other animal species.

This seminar will cover the process for obtaining federal government approval for marketing new animal drug products that are under the jurisdiction of the FDA, and also briefly covers animal products that are regulated by other federal agencies. For example, animal vaccines, animal disease diagnostic devices and some animal biologics are regulated by the U.S. Department of Agriculture, and some flea and tick control products are regulated by the Environmental Protection Agency.

This two-day interactive seminar will provide attendees with an understanding of the FDA's veterinary drug approval process. The group size is small, generally between 8 and 20 people, with plenty of opportunities to ask questions and discuss issues or challenges that the attendees have experienced.

Learning Objectives:

Key goals of the seminar will include learning:

• How the U.S. Food and Drug Administration (FDA) regulates animal drug products.
• How FDA's Center for Veterinary Medicine is organized.
• The process by which veterinary drug products are reviewed and approved.
• How to open an Investigational New Animal Drug (INAD) File.
• The FDA's various user fees, what fee waivers are available, and how to request a fee waiver.
• The various technical sections included in a New Animal Drug Application (NADA).
• What information is needed to substantiate product characterization, target animal safety and effectiveness.
• An overview of FDA's rules governing chemistry, manufacturing and controls (CMC).
• The various components of an animal field study to support product approval.
• How animal feed, veterinary devices, OTC drug products and nutritional supplements are regulated in the U.S.

Who Should Attend:

This course is designed primarily for people tasked with developing new animal drugs for an animal health company or a human pharmaceutical company. This includes individuals responsible for overseeing regulatory affairs, developing veterinary drug products, or evaluating new technologies or applications. Among others, this includes:

• Personnel new to the Animal Health Industry
• CRO professionals
• Entrepreneurs looking to add value to their products
• Regulatory professionals
• Compliance professionals
• U.S. Agents of Foreign Corporations
• Legal Professionals
• Financial Advisors and Institutional Investors

Agenda:

Day 01 (9:00 AM to 1:00 PM PDT)

• Introduction to the Veterinary Drug Approval Process
• Definitions
• INAD/NADA technical sections
• Some differences between human and animal drug approval process
• FDA organization and jurisdiction
  • FDA Centers relevant to Animal Health
• Introduction to Federal Regulations (FD&CA, AMDUCA, ADAA, FDAMA)
• FDA Guidance Documents and other online resources
• Discovery/Acquisition - Preliminary Patent Protection Concerns
• INAD/NADA Phased Review
  • Open an INAD File
  • Submit Early Information
  • Phased Review of Technical Sections
• Meetings with CVM
• Brief description of cGxP (GMP, GLP, GCP)

Day 02 (9:00 AM to 1:00 PM PDT)

• Developing the NADA Technical Sections
• Chemistry, Manufacturing, Controls (CMC)
• Effectiveness
  • The 7 Major Phases of Clinical Field Studies
• Target Animal Safety (TAS)
• Human Food Safety
• Environmental Impact
• Labeling
• Freedom of Information (FOI) Summary
• All Other Information (AOI)
• Overview of Generic Animal Drugs (JINAD)
• Submissions - ANADA sections
  • CMC
  • Bioequivalence (Safety & Efficacy)
  • Human Food Safety
  • Labeling

Day 03 (9:00 AM to 1:00 PM PDT)

• Minor Use Minor Species (MUMS)
• Designation
• Indexing
• Marketing Exclusivity & Exclusive Marketing Rights
• Animal Drug User Fees and related waivers
• Animal Feed, OTC Drugs, Supplements, Medical Devices
• Animal health products regulated by USDA & EPA
• Non-Approval-Related Considerations
• Extra-Label Drug Use
• Compounding
• Noncompliance and Enforcement
• Pharmacovigilance
• Post-approval submissions for CMC changes
• Review of the Typical Steps in Veterinary Drug Development
• Because procurement is handled differently in every

For more information about this conference visit https://www.researchandmarkets.com/r/m9emns

View source version on businesswire.com: https://www.businesswire.com/news/home/20210512005823/en/